TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow

American Journal of Hematology

Volumn 88, Issue 12, 2013, Pages 1055-1061

  Alayed, Khaled ^a,b   Patel, Keyur P ^a   Konoplev, Sergej ^a   Singh, Rajesh R ^a   Routbort, Mark J ^a   Reddy, Neelima ^a   Pemmaraju, Naveen ^a   Zhang, Liping ^a   Shaikh, Abdulaziz Al ^a   Aladily, Tariq N ^a   Jain, Nitin ^a   Luthra, Rajyalakshmi ^a   Jeffrey Medeiros, L ^a   Khoury, Joseph D ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CD123 ANTIGEN; CD2 ANTIGEN; CD33 ANTIGEN; CD4 ANTIGEN; CD5 ANTIGEN; CD56 ANTIGEN; CD7 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; HLA DR ANTIGEN; METHYLPREDNISOLONE; PREDNISONE; PROTEIN; TDT PROTEIN; TEN ELEVEN TRANSLOCATION 2 PROTEIN; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACKACHE; BLASTIC NK CELL LYMPHOMA; BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM; BONE MARROW CELL; CANCER CHEMOTHERAPY; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; CORE BIOPSY NEEDLE; DYSPNEA; FEMALE; FLOW CYTOMETRY; GENE MUTATION; HEPATOSPLENOMEGALY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHADENOPATHY; MALE; MYELODYSPLASTIC SYNDROME; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; SKIN BRUISING; SKIN DEFECT; WEAKNESS;

AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, NEOPLASM; BONE MARROW; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 13; COMBINED MODALITY THERAPY; DENDRITIC CELLS; DIAGNOSIS, DIFFERENTIAL; DNA-BINDING PROTEINS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID, ACUTE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; POINT MUTATION; PROTO-ONCOGENE PROTEINS; SEQUENCE DELETION; TRANSLOCATION, GENETIC; YOUNG ADULT;

EID: 84888061596     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23567     Document Type: Article

References (27)

1. Facchetti F, Jones DM, Petrella T. Blastic plasmacytoid dendritic cell neoplasm. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008.
2. Lee JK, Schiller G. Blastic plasmacytoid dendritic cell neoplasm. Clin Adv Hematol Oncol 2012;10:60-62.
3. Julia F, Petrella T, Beylot-Barry M, et al. Blastic plasmacytoid dentritic cell neoplasm: Clinical features in 90 patients. Br J Dermatol 2013 May 4. [Epub ahead of print]
4. Herling M, Teitell MA, Shen RR, et al. TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin. Blood 2003;101:5007-5009.
5. Khoury JD, Medeiros LJ, Manning JT, et al. CD56(+) TdT(+) blastic natural killer cell tumor of the skin: A primitive systemic malignancy related to myelomonocytic leukemia. Cancer 2002;94:2401-2408.
6. Feuillard J, Jacob MC, Valensi F, et al. Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood 2002;99:1556-1563.
7. Petrella T, Bagot M, Willemze R, et al. Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): A review. Am J Clin Pathol 2005;123:662-675.
8. Pagano L, Valentini CG, Pulsoni A, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: An Italian multicenter study. Haematologica 2013;98:239-246.
9. Rauh MJ, Rahman F, Good D, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation, lacking cutaneous involvement: Case series and literature review. Leuk Res 2012;36:81-86.
10. Naoe T, Kiyoi H. Gene mutations of acute myeloid leukemia in the genome era. Int J Hematol 2013;97:165-174.
11. Jardin F, Ruminy P, Parmentier F, et al. TET2 and TP53 mutations are frequently observed in blastic plasmacytoid dendritic cell neoplasm. Br J Haematol 2011;153:413-416.
12. Zhou Y, Jorgensen JL, Wang SA, et al. Usefulness of CD11a and CD18 in flow cytometric immunophenotypic analysis for diagnosis of acute promyelocytic leukemia. Am J Clin Pathol 2012;138:744-750.
13. Herling M, Khoury JD, Washington LT, et al. A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories. Blood 2004;104:328-335.
14. Lin P, Jones D, Medeiros LJ, et al. Activating FLT3 mutations are detectable in chronic and blast phase of chronic myeloproliferative disorders other than chronic myeloid leukemia. Am J Clin Pathol 2006;126:530-533.
15. Bains A, Luthra R, Medeiros LJ, Zuo Z. FLT3 and NPM1 mutations in myelodysplastic syndromes: Frequency and potential value for predicting progression to acute myeloid leukemia. Am J Clin Pathol 2011;135:62-69.
16. Vega F, Medeiros LJ, Jones D, et al. A novel four-color PCR assay to assess T-cell receptor gamma gene rearrangements in lymphoproliferative lesions. Am J Clin Pathol 2001;116:17-24.
17. Garnache-Ottou F, Chaperot L, Biichle S, et al. Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells. Blood 2005;105:1256-1264.
18. Roos-Weil D, Dietrich S, Boumendil A, et al. Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: A retrospective study from the European Group for Blood and Marrow Transplantation. Blood 2013;121:440-446.
19. Wright KD, Onciu MM, Coustan-Smith E, et al. Successful treatment of pediatric plasmacytoid dendritic cell tumors with a contemporary regimen for acute lymphoblastic leukemia. Pediatr Blood Cancer 2013;60:38-41.
20. Reineks EZ, Osei ES, Rosenberg A, et al. CD22 expression on blastic plasmacytoid dendritic cell neoplasms and reactivity of anti-CD22 antibodies to peripheral blood dendritic cells. Cytometry B Clin Cytom 2009;76:237-248.
21. Montes-Moreno S, Ramos-Medina R, Martinez-Lopez A, et al. SPIB, a novel immunohistochemical marker for human blastic plasmacytoid dendritic cell neoplasms: Characterization of its expression in major hematolymphoid neoplasms. Blood 2013;121:643-647.
22. Garnache-Ottou F, Feuillard J, Ferrand C, et al. Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia. Br J Haematol 2009;145:624-636.
23. Boiocchi L, Lonardi S, Vermi W, et al. BDCA-2 (CD303): A highly specific marker for normal and neoplastic plasmacytoid dendritic cells. Blood 2013;122:296-297.
24. Shih AH, Abdel-Wahab O, Patel JP, Levine RL. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer 2012;12:599-612.
25. Lemonnier F, Couronne L, Parrens M, et al. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. Blood 2012;120:1466-1469.
26. Leroux D, Mugneret F, Callanan M, et al. CD4(+), CD56(+) DC2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: A study of 21 cases by the Groupe Francais de Cytogenetique Hematologique. Blood 2002;99:4154-4159.
27. Lucioni M, Novara F, Fiandrino G, et al. Twenty-one cases of blastic plasmacytoid dendritic cell neoplasm: Focus on biallelic locus 9p21.3 deletion. Blood 2011;118:4591-4594.